Ferring and RedHill Biopharma enter strategic partnership for Rebyota® and Clenpiq®

Ferring and RedHill Biopharma enter strategic partnership for Rebyota ® and Clenpiq ® The agreement with RedHill will give Rebyota and Clenpiq dedicated commercial focus and greater opportunity to reach more patients. For Ferring, the agreement marks the successful conclusion of the strategic review of Rebyota ® and supports the company’s broader transformation. Saint-Prex, Switzerland – 1 September 2026 – Ferring Pharmaceuticals and RedHill Biopharma Ltd. (Nasdaq: RDHL) today announced a strategic partnership under which RedHill will acquire exclusive global commercial rights to Rebyota ® (fecal microbiota, live – jslm) and exclusive U.S. commercial rights to Clenpiq ® (sodium picosulphate, magnesium oxide, citric acid) , both for their currently approved indications. Under the agreement, Ferring will remain the Marketing Authorisation Holder for both products and will continue to manufacture and supply them to RedHill, while RedHill will assume responsibility for their commercialisation. The addition of exclusive U.S. commercial rights to Clenpiq is expected to further strengthen RedHill’s focused gastroenterology portfolio. The agreement follows Ferring’s announcement in October 2025 that it was exploring strategic options for Rebyota as part of its ongoing transformation. The partnership represents the successful conclusion of the strategic review of Rebyota and provides both Rebyota and Clenipiq with a dedicated commercial platform to help expand their reach among patients and healthcare professionals. Rebyota was the first FDA-approved fecal microbiota product and is indicated for the prevention of recurrence of Clostridioides difficile infection in adults following antibiotic treatment for recurrent C. difficile infection. “ Finding the right strategic partner for Rebyota was important to us, both because of the innovation behind the product and, most importantly, for the patients for the patients for whom continued access matters, ” said Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, Ferring Pharmaceuticals. “ RedHill has the right focus to take Rebyota and Clenpiq forward commercially, while Ferring will continue to play an important role as marketing authorisation holder and manufacturer. This partnership is a strong example of our Enterprise Model in action, allowing us to realise the potential of our products through the right partnerships while focusing our own resources where we are best positioned to create value. ” “ Our partnership with Ferring represents another meaningful step in strengthening RedHill’s position in gastroenterology (GI). Rebyota and Clenpiq are highly complementary additions to our specialty GI portfolio and fit well with RedHill’s team commercial and development domain expertise, ” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “ We see an opportunity to expand the new products’ reach among patients and healthcare professionals, we thank Ferring for a smooth process to date and look forward to a successful collaboration. “ KYBORA acted as exclusive advisor to Ferring on this transaction. About Rebyota ® Rebyota ® ( fecal microbiota, live – jslm ) is a pre-packaged, single-dose 150 mL microbiota suspension for rectal administration consisting of a liquid mix of live microbes. Rebyota is administered by a healthcare professional in one visit. Indication Rebyota is indicated for the prevention of recurrence of Clostridioides difficile infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. difficile infection. Limitation of Use: Rebyota is not indicated for the treatment of C. difficile infection. Important Safety Information You should not receive Rebyota if you have a history of a severe allergic reaction (e.g., anaphylaxis) to Rebyota or any of its components. You should report to your doctor any infection you think you may have acquired after administration. Rebyota may contain food allergens. Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%). Rebyota has not been studied in patients below 18 years of age. Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. Please click to see the full Prescribing Information. About Clenpiq ® Clenpiq ® (sodium picosulfate , magnesium oxide, and anhydrous citric acid) oral solution is a ready-to-drink, low-volume bowel preparation used to cleanse the colon prior to colonoscopy. It combines sodium picosulfate , a stimulant laxative, with magnesium oxide and anhydrous citric acid, which form magnesium citrate, an osmotic laxative. Indication Clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and paediatric patients 9 years of age and older. Important Safety Information Clenpiq is contraindicated in patients with severe renal impairment, gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or hypersensitivity to any of its ingredients. Bowel preparations, including Clenpiq , can cause serious fluid and electrolyte disturbances, which may lead to cardiac arrhythmias, seizures and renal impairment. Patients should maintain adequate hydration before, during and after use. Particular caution is required in patients with conditions or taking medications that increase the risk of fluid and electrolyte disturbances, seizures, renal impairment or cardiac arrhythmias. Clenpiq may cause colonic mucosal ulceration and has been associated with ischemic colitis. Caution should also be exercised in patients with severe active ulcerative colitis or an impaired gag reflex due to the risk of regurgitation or aspiration. Clenpiq may reduce the absorption of other orally administered medicines. The most common adverse reactions in adults include nausea, headache, hypermagnesemia, dehydration or dizziness, and abdominal pain. In paediatric patients 9 to 16 years of age, the most common adverse reactions include nausea, vomiting and abdominal pain. Please see the full Prescribing Information and Medication Guide for Clenpiq : www.clenpiq.com About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro -oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint- Prex , Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Learn more at www.ferring.com , or connect with us on LinkedIn , Instagram and YouTube . About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. More information about the Company is available at www.redhillbio.com / X.com/RedHillBio . For more information please contact : Ferring Pharmaceuticals Björn Lindström Director Corporate Communications [email protected] RedHill Biopharma Adi Frish Chief Corporate & Business Development Officer [email protected]

The release as fetched from its publisher. ferring.com ↗